An experimental type 2 diabetes drug vying for Food and Drug Administration (FDA) approval is being tested as an add-on therapy for type 1 diabetes.
In January 2012, the FDA declined to approve dapagliflozin, also known by the brand name Forxiga, based on concerns over breast and bladder cancer. The drug’s makers, Bristol-Myers Squibb and AstraZeneca, said they will resubmit the application for approval before the end of the summer.
Meanwhile, they are testing the drug for other indications, including a treatment for type 1 diabetes. Currently, type 1 diabetes is typically treated with insulin. Drug makers say dapagliflozin is showing promise as an add-on treatment for type 1 diabetics.
Cancer risk with type 2 diabetes treatments is a real concern. In 2011, the FDA placed a black box warning on Actos after studies showed it increased the risk for bladder cancer. Recently, studies have indicated that the type 2 diabetes drugs Byetta and Januvia have been linked to cases of pancreatic disease including acute pancreatitis and pancreatic cancer.
Attorneys with Beasley Allen Law Firm are currently investigating cases of bladder cancer in patients who have used Actos, and pancreatic cancer in patients who have taken Byetta or Januvia.
Source: MedPage Today